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Insulin resistanceBackground: Obesity is not a homogeneous condition across individuals since about 25–40% of obese individuals
can maintain healthy status with no apparent signs of metabolic complications. The simple anthropometric
measure of body mass index does not always reﬂect the biological effects of excessive body fat on health, thus
additional molecular characterizations of obese phenotypes are needed to assess the risk of developing
subsequent metabolic conditions at an individual level.
Methods: To better understand the associations of free fatty acids (FFAs) with metabolic phenotypes of obesity,
we applied a targetedmetabolomics approach tomeasure 40 serum FFAs from 452 individuals who participated
in four independent studies, using an ultra-performance liquid chromatograph coupled to a Xevo G2 quadruple
time-of-ﬂight mass spectrometer.
Findings: FFA levels were signiﬁcantly elevated in overweight/obese subjects with diabetes compared to their
healthy counterparts. We identiﬁed a group of unsaturated fatty acids (UFAs) that are closely correlated with met-
abolic status in two groups of obese individuals who underwentweight loss intervention and can predict the recur-
rence of diabetes at two years after metabolic surgery. Two UFAs, dihomo-gamma-linolenic acid and palmitoleic
acid, were also able to predict the future development of metabolic syndrome (MS) in a group of obese subjects.
Interpretation: These ﬁndings underscore the potential role of UFAs in the MS pathogenesis and also as important
markers in predicting the risk of developing diabetes in obese individuals or diabetes remission after a metabolic
surgery.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).holic fatty liver disease; CVD,
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Obesity is closely associatedwith the risk of developing type 2 diabe-
tes (T2D), nonalcoholic fatty liver disease (NAFLD), and cardiovascular
disease (CVD). When the nutrient intake exceeds expenditure, tissues
such as the adipose, liver, and skeletal become saturated with lipids
and result in an increase in lipid export leading to elevated plasma
free fatty acids (FFAs) (Kahn et al., 2006; Fabbrini et al., 2010). Previous
results from epidemiologic studies have suggested that individuals with
higher plasma concentrations of FFAs were at increased risk for T2D
(Pankow et al., 2004a; Pankow et al., 2004b; Charles et al., 1997;
Paolisso et al., 1995). Higher levels of FFAs have also been linked to pe-
ripheral (muscle) insulin resistance through inhibition of insulin-
stimulated glucose uptake and glycogen synthesis (Boden, 2003). Plas-
ma FFA levels are chronically elevated in obese individuals (Boden and
Shulman, 2002) and therefore, it was hypothesized that increased FFA
levels is an important feature of obesity-associatedmetabolic syndrome
(MS) and CVD (Boden, 2011). Normalizing plasma FFA levels has beenthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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eases (Boden and Shulman, 2002; Kusunoki et al., 2006).
The metabolic abnormalities found in T2D, NAFLD, and CVD such as
glucose intolerance, hypertension, dyslipidemia, and insulin resistance
are not found in all obese or overweight individuals, and may also be
found in normal-weight individuals (St-Onge et al., 2004). Several
recent epidemiological studies reported that a subset of obese subjects
(Stefan et al., 2013) can maintain healthy metabolic phenotypes. These
metabolically healthy obese individuals were not found at increased risk
of cardiovascular diseases (CVD) or all-cause mortality over seven years
(Hamer and Stamatakis, 2012). These and other studies have led to a
restructuring of the classiﬁcation of obese individuals as either metaboli-
cally healthy (HO) or unhealthy (UO). However, the criteria for delineat-
ing obese populations into these twometabolic categories is controversial
(Kramer et al., 2013). Because obese individuals are not homogeneous in
health, simple anthropometric measure of body mass index (BMI) does
not always translate excessive body fat into its biological effects on health
(Karelis et al., 2004). Additional types of clinical and biochemical param-
eters including plasma FFA proﬁles of obese phenotypes may be useful in
assessing future risk of subsequent medical problems. Although previous
research has focused on some of the important roles of FFAs in obesity,
strong evidence linking a single or a particular group of FFAs with the in-
creased risk of MS is lacking (Boden, 2011).
The overall objective of this study was to assess the association of cir-
culating fatty acid proﬁles with the metabolic status of obese individuals.
We applied a targetedmetabolomics approach to quantitatively measure
blood concentrations of 40 different FFAs in four different groups of sub-
jects. For each subject, 17 saturated FFAs (SFAs), 10 monounsaturated
FFAs (MUFAs), and 13 polyunsaturated FFAs (PUFAs), including n−3
(omega−3) and n−6 (omega−6) PUFAs, were measured
(Supplementary Table S1). Such a targeted metabolomics study was
designed to address three speciﬁc questions related to FFAs and MS.
First, are there signiﬁcant differences in the FFA proﬁles among three
groups, each with a different metabolic status, normal weight (NW),
overweight/obese metabolically healthy (HO), and overweight/obese di-
abetic (UO) individuals? To answer this question, a cross-sectional
study measured differences in FFA proﬁles and related them to BMI and
other metabolic markers. Second, are any FFA proﬁles predictive for HO
over a ten year evolution of health changes for their progression to UO?
A longitudinal study was applied to compare baseline FFA proﬁles be-
tween individuals who remained healthy and those who developed MS
ten years later. The last two studies involved therapeutic intervention
and were used to address another question: do speciﬁc FFA patterns re-
ﬂect signiﬁcant changes in othermetabolicmarkers related to therapeuticFig. 1. Four independent studintervention over time? Serum FFA proﬁles were characterized in obese
T2D patients before and after gastric bypass surgery and in obese patients
before and after an 8week dietary intervention utilizing a very low carbo-
hydrate diet. The key result obtained from all four studies was a panel of
UFAs, dihomo-gamma-linolenic acid (DGLA) and palmitoleic acid (PA) in
particular, were predictive of the risk of developingMS or diabetes remis-
sion after metabolic surgery in a group of obese subjects, and were also
potential markers for the inﬂammatory status of the subject.
2. Materials and Methods
2.1. Study Design and Population
Four independent studies were initiated by the Shanghai Jiao Tong
University Afﬁliated Sixth People's Hospital (Fig. 1).
(1) A total of 312 subjects were selected from the Shanghai Obesity
Study (SHOS) and enrolled in a cross-sectional study (Bao et al.,
2013). The SHOSwas a prospective study designed to investigate
the occurrence and development of MS and its related diseases.
Beginning in 2009, the SHOS recruited 5000 participants from
four communities in Shanghai, China, which included a baseline
study as well as, 1.5-, 3-, and 5-year follow-up studies. Of the
312 subjects in the cohort, 132 healthy subjects were normal
weight, 107 subjects were either overweight or obese, and 73
subjects had been diagnosed with T2D complicated with
hypertension, high cholesterol or hypertriglyceridemia.
(2) 10-year longitudinal study: 62 subjects were selected from the
Shanghai Diabetes Study (SHDS) (Jia et al., 2007). The SHDS
cohort was a multi-stage stratiﬁed epidemiological study
designed to assess the prevalence of diabetes and associated
metabolic disorders. It was initiated in 1998, when 5994 individ-
uals were enrolled from two urban communities, Huayang and
Caoyang Districts in Shanghai, China, and 1250 of them complet-
ed the follow-up examination in Huayang District between 2010
and 2011. Among 1250 eligible participants, we selected 62
subjects who were overweight/obese and metabolically healthy
at baseline, of which, 50 became unhealthy overweight/obese
and 12 remained healthy overweight/obese after ten years.
(3) Metabolic surgery intervention study: 40 obese patients with
T2D were selected from the Department of Endocrinology and
Metabolism outpatient clinic. They received Roux-en-Y gastric
bypass surgery, a commonly performed operation for treating
obesity-related T2D patients. They were required to completeies used in this analysis.
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history of open abdominal surgery, a serious disease (e.g., heart
or lung insufﬁciency) that was incompatible with surgery,
acute T2D complication, severe alcohol or drug dependency,
mental disorder, an unstable psychiatric illness, or who was at
relatively high surgical risk (e.g., with an active ulcer) was ex-
cluded. A second year outcome evaluation was also performed
for these patients. The fasting serum specimens of these 40 sub-
jects were collected for FFA analysis at ﬁve time points, including
baseline before the metabolic surgery, and at month 1, 3, 6, and
12 post-surgery.
(4) Dietary intervention study: the eight-week very low carbohy-
drate diet intervention study (VLCD) was conducted by initially
recruiting 53 obese metabolically healthy volunteers from the
Department of Endocrinology and Metabolism outpatient clinic.
The details of participant recruitment and dietary intervention
(e.g., food composition and supplementation) have been
described previously (Gu et al., 2013a; Gu et al., 2013b). Their
clinical characteristics and metabolic markers were examined
during the dietary intervention. Based on these records, 38 of
the 53 subjects who completed the eight-week intervention
study were selected because only their serum samples at base-
line and eight weeks after intervention were available for FFA
analysis.
All the studies were conducted with ethical approval from the
Shanghai Jiao TongUniversity Afﬁliated Sixth People's Hospital. Written
informed consent was obtained from participants prior to inclusion in
the study. A cutoff point of BMI 28 kg/m2 was used to deﬁne obesity
(≥28 kg/m2), a BMI of 24 kg/m2 was used to deﬁne overweight
(≥24 kg/m2) and normal weight was deﬁned as (b24 kg/m2) based on
the recommendation of overweight and obesity for Chinese population
(Bei-Fan, 2002). Clinical characteristics andmetabolicmarkers associat-
ed with MS were examined for all the participants in four independent
studies, including fasting glucose, oral glucose tolerance test (2h-glu-
cose or OGTT), insulin level, systolic and diastolic blood pressures (SBP
and DBP), total cholesterol (TC) and triglycerides (TG), and high-
density lipoprotein and low-density lipoprotein (HDL and LDL). “Meta-
bolically healthy” was deﬁned as having all of the following: FPG ≤6.1
mmol/L, OGTT ≤7.8 mmol/L and no previous history of diabetes; SBP/
DBP b140/90 mmHg and no previous history of high blood pressure;
fasting plasma TG b1.7 mmol/L and fasting plasma HDL ≥0.9 mmol/L
(men) or ≥1.0 mmol/L (women), and no previous history of high cho-
lesterol (TC b5.18 mmol/L); no cardiovascular or endocrine disease his-
tory. Failure to meet all of the criteria was classiﬁed as “metabolically
unhealthy”.
2.2. Sample Preparations and FFA Analysis
All the serum specimens were stored at −80 °C until analyzed.
There were a total of 650 specimens available for FFA analysis: 200
from ﬁve time points of metabolic surgery, 76 from two time points of
diet intervention, 312 from the cross-sectional study, and 62 from the
longitudinal study. Reference standards of these FFAs, an internal stan-
dard C19:0-d37, and LC-MS-grademethanol, acetonitrile, water, ammo-
nium acetate, and formic acid were purchased from Sigma-Aldrich
(Fisher Scientiﬁc, Fair Lawn, NJ). In addition to the internal standard, a
mixture of all the reference standards at an appropriate concentration
was prepared and run after every ten serum samples for quality control.
For all samples, we applied the same protocols to identify and quantify
the 40 FFAs using a UPLC-QTOF-MS. The quality control data were as
follows: the relative standard deviation (RSD) values of the internal
standard were 14.9%, 16.1%, and 6.62%, and the average RSD values of
the 40 FFAs in quality control samples were 12.6%, 14.9%, and 14.35%,
during the analysis of samples for the metabolic surgery, the dietaryintervention and cross-sectional study combined analysis, and in the
longitudinal study, respectively.
Serum samples from the four studies were processed and analyzed
using the same protocol (Trufelli et al., 2011; Puttmann et al., 1993).
Speciﬁcally, each sample aliquot of 40 μL was mixed with 10 μL of
isotope labeled internal standard (5 μg/mL C19:0-d37), and 500 μL of
isopropyl/hexane (v/v=80/20) with 2% phosphate (2M). The mixture
was extracted with 400 μL of hexane and 300 μL of water. After
centrifugation, an aliquot of 400 μL of supernatant was transferred
to an Eppendorf microcentrifuge tube and the remaining mixture
was further extracted with additional 400 μL of hexane. After
centrifugation, an aliquot of 500 μL of supernatant was combined
with the ﬁrst supernatant and dried under vacuum. The residue
was reconstituted with 80 μL of methanol, ﬁltered with 0.22-μm
membrane (EMD Millipore, Billerica, MA) and then analyzed using
UPLC-QTOF-MS.
The set-up parameters for the UPLC-QTOF-MS analysis were as
follows. A BEH C18 (2.1 mm × 100 mm, 1.7 μm) chromatographic col-
umn was used for separation with column temperature set at 40 °C.
The elution solvents were water (A) and acetonitrile/isopropyl (v/
v = 80/20, B) with a ﬂow rate of 400 μL/min. The initial gradient
was 70% B and kept for 2 min; increased to 75% B in 3 min; increased
to 80% in 5 min; increased to 90% in 3 min; increased to 99% in 3 min
and kept at 99% for 5 min before switching back to initial condition.
The MS was operated at a negative electrospray ionization
mode with a capillary voltage of 2.5 kV. The sample cone and the
extraction cone were set at 55 V and 4 V, respectively. The source
temperature was set to 150 °C, and the desolvation temperature
was set to 450 °C with a desolvation gas ﬂow rate of 650 L nitrogen
per hour.2.3. Statistical Analysis
The raw data produced by UPLC-QTOF-MS were initially processed
using TargetLynx applications manager version 4.1 (Waters Corp.,
Milford, MA) to detect peak signals, obtain calibration equations, and
calculate the concentration of each FFA. Manual examination and cor-
rection were needed to ensure data quality. All statistical computing
and graphics were carried out using R version 3.2.1 and SIMCA 13.0.1
software (Umetrics, Sweden).
Prior to the statistical analysis, we examined the distribution of each
continuous variable (i.e., clinical characteristics, metabolic markers and
FFAs) using the Shapiro–Wilk test, and found that 90% of the variables
deviated from normality, thus non-parametric tests were used for this
study. We used the Mann–Whitney U test to compare each metabolic
marker or FFA between two sample sets, such as HO and UO groups in
the cross-sectional study. In the metabolic surgery study, the Kruskal–
Wallis test was used to compare the metabolic changes of obese
subjects at ﬁve different time points. Variables with p-values b 0.05
were considered statistically signiﬁcant in our study. We calculated
the Spearman rank correlation coefﬁcients to measure the relationships
between the circulating levels of FFAs, as well as between FFAs and
metabolic variables. Their correlations were further visualized using
heat map and analyzed using hierarchical clustering. Multivariate
logistic regressionmodelswere used to estimate the relative risk of hav-
ing diabetes recurrence after metabolic surgery or developingMS at dif-
ferent FFA levels, adjusting for age, sex, BMI and other confounding
factors. Also, p values b 0.05 were considered signiﬁcant from logistic
regression analysis. To evaluate the similarities/differences of FFA
proﬁles between HO and UO groups in the cross-sectional study, a
supervised multivariate model called orthogonal partial least square
discriminant analysis (OPLS-DA) was built based on their overall
metabolic proﬁles. We further calculated the ROC curve areas of FFAs
to evaluate their performance in discriminating HO and UO groups in
the cross-sectional study.
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3. Results
3.1. Signiﬁcantly Increased FFA Levels Were Observed in Overweight/Obese
Subjects With T2D
In the cross-sectional study, comprising 132 normal-weight (NW),
107 healthy overweight/obese subjects (HO), and 73 overweight/
obese subjects diagnosed with T2D (here referred to as unhealthy
obese subjects, UO), we observed that therewere signiﬁcant differences
among the three groups according to BMI and key metabolic markers
(Table 1). From our metabolic analysis, NW and HO groups shared
similar FFA proﬁles due to their healthy metabolic status; however,
the FFA proﬁles were signiﬁcantly elevated in the UO group compared
to the HO or NW group (Supplementary Table S2). Using a multivariate
analysis model (i.e., OPLS-DA), we also noticed that individuals in the
UO group were well separated from those in the HO group based on
their FFA levels (Fig. 2a). The Spearman correlation analysis indicated
their close correlations between FFAs and metabolic markers, and
most of UFAs showed strong and positive correlations with them,
e.g., glucose and HOMA-IR levels (Fig. 2b). The power of individual
FFA in discriminating unhealthy subjects from their healthy
counterparts was further compared according to their p-values from
Mann–Whitney test, fold change ratios and calculated ROC areas
(Fig. 2c). Among them, DGLA (C20:3 n6) stood out due to the highest
ROC value (0.92, 95% CI: 0.88–0.96) and the smallest p value
1.09 × 10−21.
3.2. A Panel of FFAs Were Predictive of the Risk of Developing Future MS in
Overweight/Obese Subjects
The longitudinal study consisted of 62 healthy obese subjects
selected from the SHDS study. Its purpose was to further examine theTable 1
The clinical characteristics and metabolic markers of NW, HO and UO subjects in the cross-sec
Name NW HO
Male (female) 47(85) 39(68)
2h-glucose (mmol/L) 5.55 ± 0.09 5.74 ± 0.1
Fasting glucose (mmol/L) 5 ± 0.04 5.14 ± 0.03
0.5h-glucose (mmol/L) 8.18 ± 0.14 8.55 ± 0.14
TG (mmol/L) 0.82 ± 0.02 0.99 ± 0.03
TC (mmol/L) 4.28 ± 0.05 4.26 ± 0.05
Age (years) 45.721 ± 0.852 46.269 ± 0.788
SBP (mmHg) 114.61 ± 0.95 116.01 ± 1.06
HOMA-IR 1.3 ± 0.05 2.09 ± 0.1
HOMA-β 80.4 ± 3.16 115.8 ± 6.48
0.5h-insulin (μU/mL) 50.17 ± 2.14 67.75 ± 3.51
2h-insulin (μU/mL) 27.83 ± 1.47 36.82 ± 2.32
LDL (mmol/L) 2.47 ± 0.04 2.69 ± 0.04
DBP (mmHg) 72.21 ± 0.67 74.6 ± 0.82
Waist (cm) 72.72 ± 0.4 87.9 ± 0.75
Uric acid (μmol/mL) 274.47 ± 5.17 297.16 ± 7.29
HDL (mmol/L) 1.63 ± 0.03 1.4 ± 0.03
Fasting insulin (μU/mL) 5.78 ± 0.23 9.07 ± 0.41
ALT (U/L) 15.21 ± 0.6 19.13 ± 0.81
BMI (kg/m2) 20.51 ± 0.06 27.11 ± 0.18
Creatinine 65.45 ± 1.2 65.21 ± 1.37
AST (U/L) 19.7 ± 0.4 20.27 ± 0.5
Urea 4.87 ± 0.1 4.85 ± 0.11
Note: values represent means± SEM. P1, P2, P3 values are calculated usingMann–Whitney U t
tively. The variables are ordered by P3 values.performance of these differential FFAs found in the cross-sectional
study in predicting the risk of future MS. The selected 62 overweight
subjects had normal metabolic markers at baseline and 50 of them de-
veloped MS (UO) while 12 remained healthy (HO) according to their
re-evaluation after ten years. There were no differences between these
two groups at baseline according to their metabolic markers. However,
the baseline serum levels of six FFAs (i.e., ﬁve UFAs and one SFA) were
signiﬁcantly increased or decreased in the UO group (Table 2). Logistic
regressionmodels adjusting for age, sex, BMI, HOMA-IR and fasting glu-
cose were ﬁtted. This result further conﬁrmed that the baseline concen-
trations of these FFAs are predictive of the development of future MS in
these subjects, including the most signiﬁcant UFA found in the cross-
sectional study, DGLA.
3.3. Metabolic Surgery Produced Signiﬁcant Changes of UFA Proﬁles That
Also Predicted T2D Remission in Obese Subjects
Among 40 subjects, 95% of them (n = 38) showed diabetes remis-
sion as deﬁned by a normal glycated hemoglobin concentration
(HbA1c b6.5%) in the absence of medication within the ﬁrst year. At
the 2nd year follow-up examination, of the 38 subjects that achieved
T2D remission, 28 subjects continued in remission while the remaining
10 patients suffered recurrence of T2D. First, we studied the 38 individ-
uals who received diabetes remissionwithin one year in order to corre-
late their FFA levels with improved metabolic markers. The key
metabolic markers of these subjects returned to normal levels at 3
months after surgery and maintained the normal levels at 6 and 12
months (Table 3). While mild changes in SFA levels were observed in
the participants, UFAs were progressively and signiﬁcantly decreased
during the 12 months after surgery. Particularly, MUFAs and n−6
PUFAs decreased concurrently with key metabolic markers, e.g., TC,
TG, HbA1c, glucose, insulin and HOMA-IR (Supplementary Table S3
and Figure S1A–E). Then we calculated the pairwise correlation coefﬁ-
cients between circulating FFAs andmetabolicmarkers. Based on the hi-
erarchical clustering of their correlations, SFAs, UFAs and metabolic
markers formed three major clusters (Fig. 3a) while UFAs had closer
correlations with metabolic markers. To compare the correlations of
SFAs and UFAs with each metabolic marker, we selected their largest
coefﬁcient with statistical signiﬁcance to represent their strongest
relationship with each metabolic marker. The result showed that UFAstional study.
UO P1 P2 P3
37(36)
14.88 ± 0.5 1.52E-01 3.76E-32 8.69E-30
8.04 ± 0.3 1.55E-03 1.25E-28 2.56E-25
13.34 ± 0.41 3.42E-02 1.49E-24 5.71E-22
2.38 ± 0.17 4.99E-05 9.26E-26 1.31E-18
5.44 ± 0.11 6.82E-01 1.64E-16 1.93E-16
57.111 ± 0.846 7.72E-01 1.42E-14 9.01E-15
137.54 ± 2.57 3.48E-01 1.16E-16 4.48E-14
3.89 ± 0.24 5.32E-11 2.32E-25 6.30E-12
61.64 ± 4.21 5.96E-07 2.60E-04 8.91E-12
38.76 ± 3.58 1.80E-05 3.62E-05 7.89E-11
69.67 ± 5.9 1.27E-03 1.34E-14 1.63E-08
3.29 ± 0.1 5.51E-04 3.15E-12 1.26E-07
81.91 ± 1.63 5.97E-03 9.29E-09 3.74E-05
92.39 ± 0.82 2.86E-35 7.56E-32 1.01E-04
328.95 ± 7.78 3.03E-02 1.13E-08 1.05E-03
1.27 ± 0.03 3.27E-08 4.53E-15 1.34E-03
11.03 ± 0.6 5.70E-11 6.25E-16 8.67E-03
22.92 ± 1.19 7.59E-05 3.62E-09 1.44E-02
27.68 ± 0.3 2.78E-40 2.28E-32 1.37E-01
64.05 ± 1.72 7.60E-01 4.35E-01 6.12E-01
20.7 ± 0.66 3.49E-01 2.02E-01 7.02E-01
4.81 ± 0.1 7.58E-01 7.77E-01 9.97E-01
est to compare the FFA differences between NW and HO, NW and UO, HO and UO, respec-
Fig. 2. FFA analysis in the cross-sectional study. (a) The 3D OPLS-DA scores plot showing the groupings of HO (blue), and UO (red) individuals based on their FFA proﬁles. (b) Heat map of
correlation coefﬁcients between FFAs andmetabolic markers. FFAs are ordered by their average correlationswithmetabolic markers. FFAs belonging to UFA or SFA group are indicated by
red or green dots. (c) Bar plots of the fold changes, ROC areas, and normalized p values (−log p/maximum) calculated between HO and UO group.
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(Fig. 3b). Also, the number of individual UFAs that had statistically
signiﬁcant correlations with each metabolic marker is more than that
of SFAs, as indicated in Fig. 3b.
Two years after surgery, a total of 10 individuals had diabetes recur-
rence (recurrence group, REG), 2 had T2D initially without remission
(also in the REG) and 28 subjects received complete diabetes remission
(healthy group, HG). The HG group had lower HbA1c level at baseline
and experienced more weight loss during the two years, compared to
the REG group (Supplementary Table S4). In addition, a group of UFAs
were signiﬁcantly elevated in theREG groupwhile SFA levelswere com-
parable between two groups (Fig. 3c). The logistic regression models
were ﬁtted to assess the associations between baseline FFA levels and
future recurrence/remission of diabetes after surgery, adjusting for
age, sex, BMI, HbA1c, weight loss and HOMA-IR. Five UFAs weredetermined to be potential predictive markers for a therapeutic
response to metabolic surgery (Supplementary Table S5).
3.4. Dietary Intervention Resulted in Signiﬁcant Improvements in Clinical
Markers and 9 UFAs
In the dietary intervention study, 38 obese subjects participated in
an eight-week, very low carbohydrate diet (VLCD) intervention and
showed beneﬁcial effects, such as signiﬁcant improvement of clinical
characteristics and metabolic markers, including BMI, waist circumfer-
ence, blood pressure, TG, and HOMA-IR (Supplementary Table S6).
Similar to the results from the metabolic surgery study, the overall
UFA levels, MUFA and n−6 PUFAs in particular, were decreased after
intervention. In contrast, seven SFAs and an n−3 PUFA were increased
signiﬁcantly (Fig. 4a). Among nine UFAs of statistical signiﬁcance, we
Table 2
The baseline clinical characteristics, metabolic markers, and FFA levels of participants in the longitudinal study.
Name HO UO FC P1 OR (95% CI) P2
Male (female) 1(11) 15(35)
Age 39.92 ± 3.66 43.94 ± 1.83 1.02 5.80E-01
BMI 26.88 ± 0.47 26.89 ± 0.37 0.99 4.87E-01
SBP 109.22 ± 3.78 115.57 ± 1.7 1.05 3.74E-01
DBP 72.31 ± 2.55 74.33 ± 0.77 1 7.87E-01
Fasting glucose 4.87 ± 0.12 4.7 ± 0.06 0.96 2.30E-01
2h-glucose 5.1 ± 0.19 5.26 ± 0.16 0.99 7.01E-01
Fasting insulin 7.4 ± 0.85 7.1 ± 0.48 0.85 4.65E-01
2h-insulin 43.6 ± 11.43 39.42 ± 3.51 0.91 9.50E-01
HOMA-IR 1.61 ± 0.19 1.48 ± 0.1 0.83 3.83E-01
TG 0.94 ± 0.09 1.14 ± 0.04 1.28 4.99E-02
TC 4.17 ± 0.13 4.08 ± 0.07 0.93 4.98E-01
HDL 1.31 ± 0.06 1.34 ± 0.03 1.01 5.09E-01
LDL 2.74 ± 0.13 2.67 ± 0.06 0.92 5.04E-01
SFA 164.16 ± 20.52 166.65 ± 7.08 1.21 5.04E-01
C8:0 0.14 ± 0.02 0.13 ± 0.02 0.68 2.28E-01
C10:0 0.07 ± 0.01 0.07 ± 0.01 0.91 5.39E-01
C12:0 0.23 ± 0.04 0.24 ± 0.02 0.99 9.93E-01
C14:0 10.87 ± 0.71 9.99 ± 0.22 0.89 1.73E-01
C15:0 1.47 ± 0.13 1.41 ± 0.05 1.07 9.79E-01
C16:0 74.74 ± 11.05 82.59 ± 4.69 1.27 2.81E-01
C17:0 3.31 ± 0.25 3.28 ± 0.09 1.1 4.93E-01
C18:0 69.35 ± 8.64 65.12 ± 2.28 1.15 7.15E-01
C19:0 0.39 ± 0.03 0.38 ± 0.01 1.05 9.22E-01
C20:0 0.91 ± 0.06 0.86 ± 0.02 1 4.28E-01
C22:0 0.07 ± 0.01 0.07 ± 0 0.9 5.51E-01
C24:0 0.01 ± 0 0.01 ± 0 0.52 1.58E-02 0.19 (0.06–0.66) 8.19E-03
C14:0 iso 0.15 ± 0.03 0.16 ± 0.01 0.98 9.64E-01
C15:0 iso 0.94 ± 0.07 0.89 ± 0.03 1.02 5.51E-01
C16:0 iso 0.67 ± 0.06 0.64 ± 0.02 1.04 9.50E-01
C17:0 iso 0.51 ± 0.03 0.51 ± 0.02 1.02 9.79E-01
C18:0 iso 0.33 ± 0.03 0.3 ± 0.01 1.04 6.75E-01
MUFA 26.06 ± 4.23 33.98 ± 2.01 1.57 2.78E-02
C14:1 n5 0.4 ± 0.09 0.45 ± 0.04 1.02 3.14E-01
C16:1 n7 1.97 ± 0.28 2.63 ± 0.14 1.46 3.04E-02 4.32 (1.39–13.43) 1.16E-02
C16:1 t9 0.1 ± 0.01 0.11 ± 0.01 0.81 7.02E-01
C17:1 n7 0.25 ± 0.04 0.32 ± 0.02 1.43 7.33E-02
C18:1 n9 21.82 ± 3.73 28.9 ± 1.78 1.61 2.10E-02 1.10 (1.01–1.20) 2.85E-02
C18:1 t9 0.3 ± 0.03 0.26 ± 0.01 0.82 1.62E-01
C19:1 n9 0.06 ± 0.01 0.07 ± 0 1.33 1.15E-01
C20:1 n9 0.65 ± 0.11 0.74 ± 0.05 1.16 1.62E-01
C22:1 n9 0.5 ± 0.11 0.49 ± 0.06 0.83 8.52E-01
C24:1 n9 0.02 ± 0.01 0.03 ± 0 0.93 7.02E-01
n−3 PUFA 26.68 ± 3.37 32.92 ± 1.72 1.18 1.42E-01
C18:3 n3 0.65 ± 0.12 0.7 ± 0.04 1.29 2.97E-01
C20:5 n3 2.23 ± 0.43 2.81 ± 0.28 1.33 4.28E-01
C22:3 n3 0.01 ± 0 0.02 ± 0 1.44 3.40E-01
C22:5 n3 0.17 ± 0.02 0.26 ± 0.03 1.45 2.78E-02 3.98 (1.03–15.32) 4.49E-02
C22:6 n3 23.62 ± 2.87 29.13 ± 1.42 1.16 1.46E-01
n−6 PUFA 67.75 ± 11.7 93.57 ± 8.04 1.54 4.90E-02
C18:2 n6 46.93 ± 8.92 62.72 ± 5.14 1.43 6.78E-02
C18:3 n6 2.85 ± 0.39 3.48 ± 0.15 1.26 1.11E-01
C20:2 n6 0.73 ± 0.09 0.96 ± 0.05 1.51 2.10E-02 1.34 (1.02–1.77) 3.61E-02
C20:3 n6 1.72 ± 0.33 2.80 ± 0.27 1.81 1.03E-02 2.21 (1.02–4.82) 4.52E-02
C20:4 n6 6.85 ± 0.91 9.71 ± 1.62 1.29 6.26E-02
C22:2 n6 0.03 ± 0 0.03 ± 0 1.12 3.14E-01
C22:4 n6 0.19 ± 0.03 0.27 ± 0.02 1.39 2.31E-02
C22:5 n6 1.11 ± 0.14 1.53 ± 0.11 1.27 5.54E-02
Note: values represent means ± SEM. The concentration unit of FFAs is μg/mL. FC values are fold changes ratios of medians in UO over HO group. P1 values are calculated using Mann
Whitney-U test, and highlighted in bold if p b 0.05. OR (95% CI) are odd ratios (95% conﬁdence intervals) for metabolic syndrome from logistic regression models. These models are ad-
justed for age, sex, BMI, HOMA-IR, and fasting glucose. P2 values are calculated from logistic regression models.
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markers in the metabolic surgery study, including PA (C16:1 n7),
heptadecenoic acid (C17:1 n7, HA), γ-linolenic acid (C18:3 n6, GLA),
and DGLA (Fig. 4b–e).
4. Discussion
Using a targetedmass spectrometrymetabolomics approach, we ana-
lyzed serum samples of a total of 452 subjects from four independent
studies and identiﬁed a panel of UFAs whose fasting serumconcentrations at routine examination delineates the metabolic status
of obese individuals. In the cross-sectional study, FFA levels were found
signiﬁcantly elevated in overweight/obese subjects with T2D compared
to their healthy counterparts. A panel of UFAs, DGLA in particular, was
closely associated with metabolic markers, and was a signiﬁcant marker
to distinguish metabolically healthy and unhealthy individuals. We also
analyzed the baseline FFAs of subjects from a longitudinal study, and
found that fasting concentrations of a similar panel of UFAswere elevated
up to 10 years before the onset of MS. Finally, in the two weight loss in-
tervention studies, obese participants experienced signiﬁcant beneﬁcial
Table 3
The clinical characteristics and metabolic markers of obese subjects before and after metabolic surgery.
Baseline Month 1 Month 3 Month 6 Month 12 p Value
Male (female) 18 (20) 18 (20) 18 (20) 18 (20) 18 (20) /
Age (years) 44.40 ± 1.96 44.40 ± 1.96 44.40 ± 1.96 44.40 ± 1.96 44.40 ± 1.96 /
BMI (kg/m2) 32.25 ± 0.67 28.04 ± 0.58** 25.84 ± 0.55** 24.59 ± 0.48** 24.37 ± 0.43** 1.93E-15
HOMA-IR 8.55 ± 1.23 4.14 ± 0.73** 2.04 ± 0.26** 1.73 ± 0.19** 1.77 ± 0.19** 2.30E-15
Total FFA (μmol/L) 509.92(27.59) 861 (41.17)** 534.59(42.11) 377.84 (20.50)** 428.21 (29.56)* 5.59E-15
Waist (cm) 107.33 ± 2.18 95.97 ± 1.65** 89.83 ± 1.7** 86.24 ± 1.54** 85.63 ± 1.37** 1.26E-13
Fasting insulin (μU/mL) 25.05 ± 3.69 12.92 ± 1.72** 7.94 ± 0.86** 7.02 ± 0.7** 6.99 ± 0.68** 1.31E-12
2h-insulin (μU/mL) 108.26 ± 13.7 20.94 ± 2.9** 24.02 ± 3.66** 31.21 ± 5.37** 23.09 ± 3.14** 5.68E-12
TG (mmol/L) 2.15 ± 0.2 1.5 ± 0.11* 1.22 ± 0.09** 1.09 ± 0.06** 0.97 ± 0.06** 6.81E-11
2h-glucose (mmol/L) 12.03 ± 0.64 7.41 ± 0.41** 7.12 ± 0.48** 6.73 ± 0.47** 6.7 ± 0.44** 2.26E-09
HDL (mmol/L) 1.03 ± 0.03 0.97 ± 0.03* 1.03 ± 0.03 1.16 ± 0.03* 1.26 ± 0.04** 4.20E-08
Fasting glucose (mmol/L) 7.84 ± 0.4 6.77 ± 0.3* 5.7 ± 0.23** 5.45 ± 0.17** 5.69 ± 0.18** 5.31E-08
HbA1c (%) 7.53 ± 0.28 6.68 ± 0.19* 5.96 ± 0.16** 5.81 ± 0.12** 5.89 ± 0.16** 6.50E-08
TC (mmol/L) 5.18 ± 0.17 4.91 ± 0.17 4.32 ± 0.13** 4.24 ± 0.12** 4.28 ± 0.13** 1.36E-05
SBP (mmHg) 137.34 ± 2.93 129.17 ± 2.72 124.45 ± 2.33* 121.11 ± 2.28** 119.97 ± 1.99** 2.40E-05
DBP (mmHg) 86.94 ± 1.99) 81.58 ± 1.56* 80.52 ± 1.81* 76.24 ± 1.62** 77.82 ± 1.39** 1.34E-04
LDL (mmol/L) 3.18 ± 0.15) 3.14 ± 0.15 2.62 ± 0.11* 2.53 ± 0.12* 2.48 ± 0.1** 1.34E-04
HOMA-β 158.55 ± 27.6 93.22 ± 10.27 95.89 ± 10.77 91.81 ± 11.12 77.52 ± 7.91* 3.26E-01
Note: values representmeans±SEM. Symbols * (p b 0.05) or ** (p b 0.001) indicate that the signiﬁcant difference between a follow-up time andbaseline usingMann–WhitneyU test. p Values
are calculated to test the differences among ﬁve time points using Kruskal–Wallis test, and highlighted in bold if p b 0.05. The variables are ordered by p values. HOMA-IR is calculated by the
formula: [fasting insulin (μU/mL) × fasting glucose (mmol/L)] / 22.5. HOMA-β is calculated by the formula: [20 × fasting insulin (μU/mL)]% / [fasting glucose (mmol/L)− 3.5].
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panel of UFAs decreased signiﬁcantly in response to the surgical or
dietary interventions.
UFAs, as compared to SFAs, were decreased more signiﬁcantly after
weight loss interventions, and increased more signiﬁcantly in obese
subjects with MS. Additionally, UFA signatures were more closely asso-
ciated with metabolic markers. To date, SFAs have been generallyFig. 3. FFA analysis in the metabolic surgery study. (a) Heat map of correlation coefﬁcients bet
represents different classes of variables: UFA (red), metabolic markers (blue) and SFA (green)
each metabolic marker. The single number highlighted in red or green indicates the number o
0.05). (c) Fold change plot of baseline FFAs (REG/HG). FFAs labeled with red dots were signiﬁ
from logistical regression analysis (p b 0.05).thought to have detrimental effects on health. However, conﬂicting
evidence was reported regarding the effects of high SFA intake on the
risk of diabetes (Micha and Mozaffarian, 2010). A large cohort study
recently suggested that different individual plasma phospholipid SFAs
were not homogeneous and associated with incident T2D in opposite
ways (Forouhi et al., 2014). They reported that even-chain SFAs (those
containing an even number of carbon atoms) including palmitic acidween circulating FFAs, as well as between FFAs and metabolic markers. The color of dots
. (b) Line plot of the largest correlation coefﬁcient between representatives SFA/UFA with
f UFAs or SFAs that had statistically signiﬁcant correlations with metabolic markers (p b
cantly different between two groups (p b 0.05). Symbol * indicates statistical signiﬁcance
Fig. 4. FFA analysis of obese subjects in the dietary intervention study. (a) Bar plot of fold change ratios of signiﬁcant FFAs (p b 0.05), whichwere calculated by dividing themedian level of
each FFA at the 8thweek over the baseline level−1. Positive and negative values represent elevation and depletion of FFA concentrations after intervention. FFAs belonging to UFA or SFA
group are indicated by red or green dots. (b–e) Box plots of four UFAs at baseline and 8 weeks. The unit of FFA concentrations is μg/mL.
1520 Y. Ni et al. / EBioMedicine 2 (2015) 1513–1522(C16:0) were positively associated and odd-chain (those containing an
odd number of carbon atoms) and longer-chain SFAs (those with 13 to
21 carbon atoms) were inversely associated with incident diabetes. In
our study, most SFAs did not show strong correlations with metabolic
markers, except C16:0 thatwas decreased signiﬁcantly in obese individ-
uals aftermetabolic surgery, and increased signiﬁcantly in the UO group
of the cross-sectional study. Palmitic acid has long been thought to be
the major culprit of insulin resistance (Reynoso et al., 2003; Mordier
and Iynedjian, 2007). Palmitate in plasma phospholipid and erythrocyte
membranes phospholipid was prospectively associated with higher
diabetes risk in several longitudinal studies (Ma et al., 2015; Wang
et al., 2003; Patel et al., 2010). Increased amounts of FFAs, especially
palmitate from either dietary intake or adipose tissue lipolysis, are
delivered into the liver cells via speciﬁc fatty acid transport proteins
(FATPs) in their cell membranes (Supplementary Figure S2A). If palmi-
tate is not oxidized and used for energy then it is used as a substrate for
de novo lipogenesis (DNL), a metabolic pathway that is normally
inhibited and usually contributes only 5% of the stored triglycerides in
the liver and which increases to 30% in MS. In obese individuals, FATPs
are upregulated in the liver and diminished in the adipose tissue
(Gruben et al., 2014; Perry et al., 2014).
Compared to SFAs, convincing evidence observed in our study was
that UFAs are more closely associated with metabolic status in obese
individuals. The ﬂuctuations of circulating FFAs in obese phenotypes
may be due to the different FA mobilization mechanisms from adipose
tissue to blood, where SFAs were found much less mobilized than
PUFAs (Connor et al., 1996). Our ﬁndings particularly highlight a panel
of UFAs that was consistently associated with metabolic status in
obese individuals across four independent studies. Two UFAs, PA andDGLA may be potential inﬂammation markers in predicting the risk of
developing MS and monitoring the metabolic status among over-
weight/obese individuals. PA has been proposed as a lipid-controlling
hormone (lipokine) used by adipose tissue to communicatewith distant
organs and regulate systemic metabolic homeostasis (Cao et al., 2008).
Increased levels of plasma PA indicate an increase in stearoyl-CoA
desaturase (SCD1) activity (increased DNL) in the liver as it is virtually
absent in the diet and thus can be used as a marker for upregulation
of this usually inhibited hepatic lipidmetabolic pathway (Supplementa-
ry Figure S2B) (Gong et al., 2011). Increased DNL means increased
formation of diacylglycerol (DAG), which, in turn, contributes to inﬂam-
mation via release of arachidonic acid (AA) from the plasmamembrane.
DGLA is a key player in the synthetic pathway for pro-inﬂammatory
series 2 prostaglandins and leukotrienes and elevated levels of this
PUFA may contribute to the inﬂammatory phenotype in obesity/MS
(Supplementary Figure S2C–D). Recently, it has been proposed that
the distinction between HO and UO groups is related to the degree of
chronic inﬂammation present (Perreault et al., 2014; Steffen et al.,
2012). This has led to several studies comparing inﬂammation markers
such as levels of TNF-α, adiponectin, leptin, resistin, C-reactive protein,
plasminogen activator inhibitor-1 and complement component c3,
between HO and UO populations (Steffen et al., 2012; Phillips and
Perry, 2013). The major conclusion derived from these studies was
that no signiﬁcant differences were seen for inﬂammation markers
between HO and NW subjects but inﬂammation markers were found
to be elevated in the UO groups. A previous study on 2848 adults
found that obese individuals had signiﬁcantly higher levels of n−6
PUFAs (e.g. DGLA, GLA, and AA) compared to normal and overweight
subjects, and DGLA showed strong associations with inﬂammatory
1521Y. Ni et al. / EBioMedicine 2 (2015) 1513–1522and endothelial activation markers in obesity, e.g. IL-6 and sICAM-1
(Steffen et al., 2012). It was also reported that a high proportion of
DGLA in serum cholesterol ester was associated with high concentra-
tions of C-reactive protein, which is a sensitive marker of low-grade in-
ﬂammation and associated with insulin resistance and T2D (Kurotani
et al., 2012).
To examine the effects of gender, age and BMI factors on FFAmetab-
olism, we performed subgroup analysis on all of the participants in the
cross-sectional study. First, we found three FFAs, i.e., C12:0, C18:1 t9
and C22:6 n3, were signiﬁcantly increased in females (n = 85) com-
pared to males (n = 47) in the NW group (Supplementary
Figure S3A–C). Second, ten SFAs were consistently increased with age
in females only (Supplementary Figure S4). Third, in terms of the BMI
factor, we analyzedmale subjects only whowere able to keep relatively
stable FFA levels over time, and found that three FFAs, i.e., C18:0, C14:1
n5 and C22:6 n3 were signiﬁcantly different between normal weight
(n = 47) and overweight/obesity (n = 39) (Supplementary
Figure S3D–F). Thus, we further conﬁrmed that these confounding fac-
tors do not affect our ﬁndings of UFAs in evaluating and predicting the
metabolic status in obesity.
Key strengths of the present study are its comprehensive design to
study the associations of circulating FFA levels with metabolic pheno-
types among several groups of obese participants. In addition, with a
complete panel of key metabolic markers measured for all the partici-
pants, we were able to compare the FFA proﬁles with themetabolic sta-
tus of the study participants. The limitation of the present study is the
medium-sized sample sets in the longitudinal study, due to the strict in-
clusion criteria that all the participants should have complete clinical re-
cords and BMI ≥25 at baseline when theywere healthy and at a 10-year
follow-up time. Future studies examining inﬂammatory marker associ-
ation with the FFA proﬁles discussed in this manuscript are being
pursued.
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